Docoh
Loading...

FHTX Foghorn Therapeutics

News

From Benzinga Pro
Foghorn Therapeutics Filed U.S. Patent Application #20220016083 'METHODS OF TREATING CANCERS'
20 Jan 22
News
View Patent Application here
Morgan Stanley Maintains Overweight on Foghorn Therapeutics, Raises Price Target to $26
15 Dec 21
News, Price Target, Analyst Ratings
Morgan Stanley analyst Vikram Purohit maintains Foghorn Therapeutics (NASDAQ:FHTX) with a Overweight and raises the price target from $23 to $26.
34 Stocks Moving In Tuesday's Mid-Day Session
14 Dec 21
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers Exicure, Inc. (NASDAQ: XCUR) rose 41.8% to $0.3830. Exicure’s Audit Committee recently concluded that Grant Corbett misreported raw data from certain R&D experiments related to XCUR-FXN preclinical program.
20 Stocks Moving in Tuesday's Pre-Market Session
14 Dec 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers MIND Technology, Inc. (NASDAQ: MIND) rose 37.2% to $1.88 in pre-market trading after the company reported it entered into a Cooperative Research and Development Agreement with the United States Navy's Naval Surface Warfare Center, Panama City Division.
59 Biggest Movers From Yesterday
14 Dec 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers SeaChange International, Inc. (NASDAQ: SEAC) jumped 128.8% to $1.72 following Bloomberg report suggesting that social video app Triller is in merger talks with Seachange.
Mid-Afternoon Market Update: Dow Tumbles Over 200 Points; BELLUS Health Shares Spike Higher
13 Dec 21
Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets
Toward the end of trading Monday, the Dow traded down 0.67% to 35,728.62 while the NASDAQ fell 0.92% to 15,487.41. The S&P also fell, dropping 0.58% to 4,684.47.
Mid-Day Market Update: Nasdaq Drops Over 100 Points; Foghorn Therapeutics Shares Surge
13 Dec 21
Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets
Midway through trading Monday, the Dow traded down 0.81% to 35,679.10 while the NASDAQ fell 0.78% to 15,509.01. The S&P also fell, dropping 0.67% to 4,680.56.
40 Stocks Moving In Monday's Mid-Day Session
13 Dec 21
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) shares climbed 83.4% to $91.52. Pfizer agreed to acquire Arena Pharmaceuticals for $100 per share in an all-cash transaction.
Mid-Morning Market Update: Markets Open Lower; Pfizer To Acquire Arena Pharmaceuticals
13 Dec 21
Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets
Following the market opening Monday, the Dow traded down 0.65% to 35,736.04 while the NASDAQ fell 0.26% to 15,590.13. The S&P also fell, dropping 0.46% to 4,690.48.
Foghorn Therapeutics Stock Surges After $1.5B Cancer Pact With Eli Lilly
13 Dec 21
Biotech, Long Ideas, News, Health Care, Contracts, Small Cap, Movers, Trading Ideas, General
Loxo Oncology, an R&D group of Eli Lilly And Co (NYSE: LLY), and Foghorn Therapeutics Inc (NASDAQ: FHTX) have collaborated to create oncology medicines by applying Foghorn's Gen
22 Stocks Moving in Monday's Pre-Market Session
13 Dec 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) rose 32.6% to $3.58 in pre-market trading after gaining more than 14% on Friday.
Lilly And Foghorn Announce Strategic Collaboration For Novel Oncology Targets Using Foghorn's Proprietary Gene Traffic Control Platform; Foghorn To Receive $300M Upfront And An Equity Investment By Lilly Of $80M At $20/Share
13 Dec 21
News, Contracts
- Establishes co-development and co-commercialization agreement on Foghorn's selective BRM program and an additional undisclosed
68 Biggest Movers From Wednesday
26 Nov 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) shares gained 689.4% to settle at $78.94 on Wednesday after the company priced its IPO at $10 per share.
Benzinga's Top Ratings Upgrades, Downgrades For November 22, 2021
22 Nov 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
HC Wainwright & Co. Initiates Coverage On Foghorn Therapeutics with Buy Rating, Announces Price Target of $25
22 Nov 21
News, Price Target, Initiation, Analyst Ratings
HC Wainwright & Co. analyst Andrew Fein initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) with a Buy rating and announces Price Target of $25.

Press releases

From Benzinga Pro
Foghorn Therapeutics Announces Chief Scientific Officer Succession
10 Jan 22
News, Health Care, Management, Press Releases
CAMBRIDGE, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined
Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Conference
7 Jan 22
News, Press Releases
CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined
Thinking about buying stock in Arena Pharmaceuticals, Bellus Health, Foghorn Therapeutics, Hexo Corp, or bluebird bio?
13 Dec 21
Opinion, Press Releases
NEW YORK, Dec. 13, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ARNA, BLU, FHTX, HEXO, and BLUE.
Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn's Proprietary Gene Traffic Control® Platform
13 Dec 21
Press Releases
INDIANAPOLIS and CAMBRIDGE, Mass., Dec. 13, 2021 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE:LLY), and Foghorn Therapeutics Inc. (NASDAQ:FHTX), today announced
Cellarity Appoints Biopharmaceutical Executive Ian Estepan to its Board of Directors
8 Dec 21
Penny Stocks, Small Cap, Press Releases
Estepan brings to Cellarity's BOD deep experience and expertise in all aspects of finance, corporate strategy, investor relations, and business development, and a dedication to directly improving patient lives through innovation in medicine
Generate Biomedicines Announces First External Equity Raise of $370 Million to Advance Its Drug Generation Platform
18 Nov 21
Penny Stocks, Small Cap, Press Releases
- Generate is harnessing the power of data and machine learning at scale to program biology, dramatically improve the human condition, and democratize biotherapeutics
Flagship Pioneering Announces Appointment of Justine Levin-Allerhand as Senior Partner, Corporate Development
15 Nov 21
Press Releases
CAMBRIDGE, Mass., Nov. 15, 2021 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today that Justine Levin-Allerhand, Ph.D., has joined the company in a newly created role as Senior
Foghorn Therapeutics to Participate at the 2021 Jefferies London Healthcare Conference
11 Nov 21
News, Health Care, Press Releases
CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (NASDAQ:FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively
Foghorn Therapeutics Provides Third Quarter 2021 Corporate Update
9 Nov 21
Earnings, Health Care, Press Releases
-- First patient dosed in phase 1 clinical trial of FHD-609, a potent and selective heterobifunctional protein degrader of BRD9, initially being developed for the treatment of synovial sarcoma -- Continue to enroll
Tessera Therapeutics Announces R&D Collaboration with Cystic Fibrosis Foundation as Part of a Portfolio of Complementary Technologies Advanced by Flagship's Pioneering Medicines to Treat Cystic Fibrosis
3 Nov 21
Penny Stocks, Small Cap, Press Releases
Tessera's Gene WritingTM Technology is Designed to Simultaneously Correct Multiple Genetic Mutations as well as to Write Genes in Their Entirety